TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28668558

Group type: EXPERIMENTAL
Intervention: Early rehabilitation (exercise therapy) for 6 to 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No referral
Number of subjects: 0
Study: 25919246

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 45

Group type: COMPARATOR
Intervention: IncobotulinumtoxinA
Number of subjects: 45
Study: 22892123

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6505
Study: 20980920

Group type: EXPERIMENTAL
Intervention: St. John's Wort (SJW) 300 mg three times a day for 14 days in volunteers
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: St. John's Wort (SJW) in patients
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo in patients
Number of subjects: 130
Study: 19526764

Group type: EXPERIMENTAL
Intervention: Sanhuang Qingxue Yin (SQY) plus conventional Western medical therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional Western medical therapy only
Number of subjects: 120
Study: 17255240

Group type: EXPERIMENTAL
Intervention: Mass oral azithromycin distribution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated villages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children treated with antibiotics
Number of subjects: 0
Study: 15475131

Group type: EXPERIMENTAL
Intervention: Biplanar insoles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cobra insoles
Number of subjects: 0

Group type: COMPARATOR
Intervention: No insole condition
Number of subjects: 0
Study: 11529282

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort Turbuhaler) 160/4.5 microg, two inhalations b.i.d.
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Budesonide plus formoterol via separate inhalers
Number of subjects: 362

Group type: COMPARATOR
Intervention: Budesonide/formoterol (Symbicort Turbuhaler) and budesonide plus formoterol via separate inhalers
Number of subjects: 362
Study: 9706854

Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg the first day followed by 100 mg per day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg per day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Doxycycline plus ibuprofen scheduled as in groups 1 and 2
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo capsule/day (control)
Number of subjects: 32
Study: 8572869

Group type: EXPERIMENTAL
Intervention: Active antihypertensive treatment with dihydropyridine felodipine, with a focus on achieving DBP < or = 90 mmHg.
Number of subjects: 10005

Group type: COMPARATOR
Intervention: Previous treatment before randomization.
Number of subjects: 10005
Study: 2143092

Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Number of subjects: 741

Group type: COMPARATOR
Intervention: Hospital outpatient management
Number of subjects: 741
Study: 354977

Group type: EXPERIMENTAL
Intervention: Ethylene vinyl acetate modified IUM
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Hydron coated IUM
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard IUM
Number of subjects: 300
Study: 30874378

Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg/d before bedtime for 2 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo before bedtime for 2 weeks
Number of subjects: 82
Study: 28579225

Group type: EXPERIMENTAL
Intervention: Point-of-care CD4 cell counts
Number of subjects: 770

Group type: COMPARATOR
Intervention: Standard-of-care CD4 cell counts
Number of subjects: 770
Study: 26066780

Group type: EXPERIMENTAL
Intervention: Standard treatment plus 12 sessions of individual music therapy (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard treatment only (n = 15)
Number of subjects: 30
Study: 23173979

Group type: EXPERIMENTAL
Intervention: Increased physical activity over 12 months
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Asthma self-management instruction
Number of subjects: 256
Study: 22308846

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (32 patients)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (24 patients)
Number of subjects: 56
Study: 19114868

Group type: EXPERIMENTAL
Intervention: Cervicovaginal secretions (CVS) from participants acquiring HIV (cases)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cervicovaginal secretions (CVS) from participants with bacterial sexually transmitted infections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cervicovaginal secretions (CVS)
Number of subjects: 0
Study: 16075184

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: All antidepressants
Number of subjects: 41

Group type: COMPARATOR
Intervention: Tricyclics
Number of subjects: 41
Study: 12834314

Group type: EXPERIMENTAL
Intervention: Extended anticoagulant therapy (6 months for temporary risk factors or 1 year for idiopathic pulmonary embolism)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Discontinue treatment
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Extended anticoagulation (for idiopathic venous thromboembolism)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Discontinue treatment (for idiopathic venous thromboembolism)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Extended anticoagulation
Number of subjects: 326
Study: 10571341

Group type: EXPERIMENTAL
Intervention: Visible endpoint burns
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Subthreshold (invisible) lesions
Number of subjects: 152

Group type: COMPARATOR
Intervention: Treated eyes (both visible burns and subthreshold lesions)
Number of subjects: 152
Study: 8911976

Group type: EXPERIMENTAL
Intervention: Glimepiride (1-8 mg once daily)
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Glibenclamide (2.5-20 mg)
Number of subjects: 1044
Study: 1725891

Group type: EXPERIMENTAL
Intervention: Nicardipine 40 mg, twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Captopril 50 mg, twice daily
Number of subjects: 20
Study: 7041654

Group type: EXPERIMENTAL
Intervention: Penicillin‐gentamicin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 49
Study: 4002803

Group type: EXPERIMENTAL
Intervention: Oral muzolimine 120 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31609422

Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD) providing 50% excess energy from fat, n = 10
Number of subjects: 20

Group type: COMPARATOR
Intervention: Eucaloric diet (control), n = 10
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (HFD and control) during immobilization
Number of subjects: 20
Study: 29172782

Group type: EXPERIMENTAL
Intervention: Tribulus terrestris
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26782031

Group type: EXPERIMENTAL
Intervention: 150 min/week of moderate-intensity aerobic exercise and twice-weekly supervised strength training
Number of subjects: 61
Study: 24684838

Group type: EXPERIMENTAL
Intervention: 0.3 mg quarterly ranibizumab
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: 0.5 mg quarterly ranibizumab
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: 0.3 mg monthly ranibizumab
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Loading phase of ranibizumab therapy
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Recurrence of intraretinal cysts during follow-up
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Recurrence of subretinal fluid during follow-up
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Baseline pigment epithelial detachments
Number of subjects: 353
Study: 22669289

Group type: EXPERIMENTAL
Intervention: TAK-875 (25, 50, 100, 200, or 400 mg, orally, once daily for 14 days)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: TAK-875
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 19495871

Group type: EXPERIMENTAL
Intervention: Viabil-covered stent
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bare Wallstent
Number of subjects: 60
Study: 18517094

Group type: EXPERIMENTAL
Intervention: Computer-mediated intervention (CIN)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Control
Number of subjects: 507
Study: 15851648

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure goal of 102 to 107 mm Hg (usual)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Mean arterial pressure goal of 92 mm Hg or less (lower)
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: Initial treatment with beta-blocker (metoprolol)
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: Initial treatment with angiotensin-converting enzyme inhibitor (ramipril)
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: Initial treatment with dihydropyridine calcium channel blocker (amlodipine)
Number of subjects: 1094
Study: 12881389

Group type: EXPERIMENTAL
Intervention: PELF
Number of subjects: 200

Group type: COMPARATOR
Intervention: FAMTX
Number of subjects: 200
Study: 10087825

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia with restricted dose of fentanyl (20 micrograms.kg‐1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Benzodiazepine-fentanyl regimen (control group)
Number of subjects: 34
Study: 8550838

Group type: EXPERIMENTAL
Intervention: Vitamin C (24 mg/min)
Number of subjects: 20
Study: 1859521

Group type: EXPERIMENTAL
Intervention: Monosialoganglioside
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 6651208

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 102

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 102

Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 102
Study: 31445039

Group type: EXPERIMENTAL
Intervention: Traction-assisted endoscopic submucosal dissection (TA-ESD)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional endoscopic submucosal dissection (ESD)
Number of subjects: 116
Study: 31237875

Group type: EXPERIMENTAL
Intervention: Pedometer-based walking intervention
Number of subjects: 1297
Study: 29438540

Group type: COMPARATOR
Intervention: Caloric restriction (CR)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caloric restriction + sleep restriction (CR + SR)
Number of subjects: 36
Study: 27045002

Group type: EXPERIMENTAL
Intervention: HTC service delivery by Village Health Teams (VHTs) integrated with family planning services.
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group providing family planning only.
Number of subjects: 256
Study: 24886409

Group type: EXPERIMENTAL
Intervention: High-dose OFS+P (30 g/d)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low-dose OFS+P (15 g/d)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (maltodextrin 15 g/d)
Number of subjects: 96
Study: 22914998

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg daily for nine months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy volunteer group (control)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 44
Study: 20837464

Group type: EXPERIMENTAL
Intervention: Internet-based tailored advice
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Control group (static web pages with general information)
Number of subjects: 2099
Study: 18598765

Group type: COMPARATOR
Intervention: 0.0% DHEA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5% DHEA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1.0% DHEA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1.8% DHEA
Number of subjects: 40
Study: 16051946

Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy‐General (FACT‐G)
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Functional Living Index‐Cancer (FLIC)
Number of subjects: 1268

Group type: COMPARATOR
Intervention: EORTC QLQ‐C30
Number of subjects: 1268
Study: 12477680

Group type: EXPERIMENTAL
Intervention: 3 mg x kg(-1) of 1% propofol and 3 mg x kg(-1) of 2.5% thiopentone (P/T)
Number of subjects: 127

Group type: COMPARATOR
Intervention: 5 mg x kg(‐1) of 1% propofol and 1 mg x kg(‐1) of lidocaine (P/L)
Number of subjects: 127
Study: 10391165

Group type: EXPERIMENTAL
Intervention: Rhomboid flap transposition
Number of subjects: 46

Group type: COMPARATOR
Intervention: Deep suturing technique
Number of subjects: 46
Study: 8728349

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day for 6 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1857482

Group type: EXPERIMENTAL
Intervention: enalapril 20 mg o.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: atenolol 50 mg o.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: chlorthalidone 12.5 mg o.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo o.d.
Number of subjects: 12
Study: 6220870

Group type: EXPERIMENTAL
Intervention: Erythromycin 1.5 percent topical solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clindamycin phosphate 1.0 percent topical solution
Number of subjects: 20
Study: 31692212

Group type: EXPERIMENTAL
Intervention: Medication Management Review service (MMR)
Number of subjects: 73
Study: 30159666

Group type: EXPERIMENTAL
Intervention: IgG anti-HEV antibody testing
Number of subjects: 1799

Group type: EXPERIMENTAL
Intervention: Age groups analysis for IgG anti-HEV positivity
Number of subjects: 1799

Group type: EXPERIMENTAL
Intervention: HEV RNA testing
Number of subjects: 1799
Study: 27512816

Group type: EXPERIMENTAL
Intervention: Passive stretching with continuous vibration (PS+VIB)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Passive stretching only (PS+CON)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both PS+CON and PS+VIB
Number of subjects: 14
Study: 24617764

Group type: EXPERIMENTAL
Intervention: Vinyl isolation bag
Number of subjects: 59

Group type: COMPARATOR
Intervention: Polyethylene wrap
Number of subjects: 59
Study: 23756585

Group type: EXPERIMENTAL
Intervention: Fortified milk (MG)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 108
Study: 19862820

Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg/d on Days 1‐21 of a 28‐day cycle)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 17697909

Group type: EXPERIMENTAL
Intervention: Deferasirox (5 to 30 mg/kg per day)
Number of subjects: 586

Group type: COMPARATOR
Intervention: Deferoxamine (DFO) (20 to 60 mg/kg per day)
Number of subjects: 586
Study: 16133467

Group type: EXPERIMENTAL
Intervention: Bipolar electrodissection tonsillectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 40
Study: 12404142

Group type: EXPERIMENTAL
Intervention: Group I (supine position after 5 minutes)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group II (lateral position for 15 minutes)
Number of subjects: 60
Study: 10453871

Group type: EXPERIMENTAL
Intervention: Trained group (participated in initial and maintenance workshops)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual group (no formal training until week 12)
Number of subjects: 30
Study: 7614647

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg.kg‐1 before CPB and before declamping of aorta)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-Methylprednisolone treated patients (control)
Number of subjects: 27
Study: 2517323

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg/day orally for 3 days, starting 1 day before X-ray examination)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 35
Study: 1013675

Group type: EXPERIMENTAL
Intervention: Metoprolol (3 X 50 mg day)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 5
Study: 31439004

Group type: EXPERIMENTAL
Intervention: VIBRA model (differentiated ART delivery package with drug refills and follow-ups by trained village health workers, and SMS notifications)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Standard care (collecting ART refills from a clinic, no SMS notifications)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: VIBRA model
Number of subjects: 262

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 262
Study: 27160412

Group type: EXPERIMENTAL
Intervention: THC:CBD oromucosal spray
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study: 24845395

Group type: EXPERIMENTAL
Intervention: Tai Chi plus usual care
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 43
Study: 23538313

Group type: EXPERIMENTAL
Intervention: Combined periprostatic nerve block (PPNB) and perianal‐intrarectal lidocaine‐prilocaine (PILP) cream
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Perianal‐intrarectal lidocaine‐prilocaine (PILP) cream
Number of subjects: 240

Group type: COMPARATOR
Intervention: Periprostatic nerve block (PPNB)
Number of subjects: 240
Study: 20579542

Group type: EXPERIMENTAL
Intervention: Baseline HDL-C levels
Number of subjects: 625477

Group type: COMPARATOR
Intervention: Control arms (not specified)
Number of subjects: 625477
Study: 18204986

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16978950

Group type: EXPERIMENTAL
Intervention: Cryo-assisted localization (CAL)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Needle-wire localization (NWL)
Number of subjects: 310
Study: 12919654

Group type: EXPERIMENTAL
Intervention: Glucocorticosteroid at a low dosage
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no glucocorticosteroid)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Treatment group (with glucocorticosteroid)
Number of subjects: 38
Study: 11057000

Group type: EXPERIMENTAL
Intervention: Perturbed trials (resistive force of 12 N)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Non-perturbed trials (baseline)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aperture variables (relative moment of final hand closure)
Number of subjects: 6
Study: 8956920

Group type: EXPERIMENTAL
Intervention: Levetiracetam (250 mg, 500 mg, 750 mg, 1,000 mg single oral dose; 250 mg b.i.d. for 3-5 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 12
Study: 7827348

Group type: EXPERIMENTAL
Intervention: Insulin management (infusion pump or split-dose therapy)
Number of subjects: 78
Study: 3294081

Group type: EXPERIMENTAL
Intervention: Aluminum-magnesium antacid (120 mmol/day)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg b.i.d.)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 30882520

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 1498
Study: 31016613

Group type: EXPERIMENTAL
Intervention: Teriflunomide sodium 10 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Leflunomide 10 mg
Number of subjects: 100
Study: 27606790

Group type: EXPERIMENTAL
Intervention: Tailored education program using touch‐screen computers
Number of subjects: 53

Group type: COMPARATOR
Intervention: Booklet education
Number of subjects: 53
Study: 29028921

Group type: EXPERIMENTAL
Intervention: SmartPilot® View-guided anaesthesia
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual practice anaesthesia
Number of subjects: 97
Study: 23706433

Group type: EXPERIMENTAL
Intervention: HemoSep device (group 1, n = 52)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional method (group 2, n = 50)
Number of subjects: 102
Study: 21330275

Group type: EXPERIMENTAL
Intervention: Smoking cessation (6- to 9-month abstinence)
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 1027
Study: 19623184

Group type: EXPERIMENTAL
Intervention: Intervention arm (specific intervention details not available)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (specific control details not available)
Number of subjects: 0
Study: 17161123

Group type: EXPERIMENTAL
Intervention: 25 mg mifepristone
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 50 mg mifepristone
Number of subjects: 83
Study: 15079120

Group type: EXPERIMENTAL
Intervention: Intraoperative intercostal nerve blockade with alcohol plus postoperative epidural analgesia with morphine (n=27)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Postoperative epidural analgesia with morphine only (n=30)
Number of subjects: 57
Study: 11199943

Group type: EXPERIMENTAL
Intervention: Divalproex sodium (valproate) augmentation with haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol alone (no-augmentation group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divalproex sodium (valproate) augmentation after 14 days (delayed-augmentation group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early-augmentation group
Number of subjects: 0
Study: 8676626

Group type: EXPERIMENTAL
Intervention: Acamprosate (1998 mg daily for bodyweight > 60 kg; 1332 mg daily for ≤ 60 kg)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 455
Study: 1737710

Group type: EXPERIMENTAL
Intervention: VA hospital-based team home care (HBHC, N = 85)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Customary care (N = 86)
Number of subjects: 171
Study: 6145189

Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 30695288

Group type: EXPERIMENTAL
Intervention: First-generation antipsychotic prescription
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Anticholinergic drug administration
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Negative symptoms (PANSS subscore)
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: PANSS disorganized factor
Number of subjects: 674
Study: 29383596

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) at 5 mg/kg at 0, 2, and 6 weeks, followed by every 8 weeks for 2 years
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-Infliximab (non-IFX)
Number of subjects: 38